Efficacy of systemic therapies for moderate-to-severe psoriasis: A systematic review and meta-analysis of long-term treatment

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 11, 2012, Pages 1331-1344

  Lucka, T C ^a   Pathirana, D ^a   Sammain, A ^a   Bachmann, F ^a   Rosumeck, S ^a   Erdmann, R ^a   Schmitt, J ^b   Orawa, H ^c   Rzany, B ^a   Nast, A ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c Statistician   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; ETANERCEPT; ETRETIN; FUMARIC ACID DERIVATIVE; INFLIXIMAB; METHOTREXATE; USTEKINUMAB;

COCHRANE LIBRARY; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; EMBASE; HUMAN; LONG TERM CARE; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELIABILITY; REVIEW; SYSTEMATIC REVIEW;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84867582191     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04492.x     Document Type: Review

References (58)

1. Roberson ED, Bowcock AM,. Psoriasis genetics: breaking the barrier. Trends Genet 2010; 26: 415-423.
2. Schafer I, Rustenbach SJ, Radtke M, Augustin J, Glaeske G, Augustin M,. Epidemiology of psoriasis in Germany-analysis of secondary health insurance data. Gesundheitswesen 2011; 73: 308-313.
3. Augustin M, Herberger K, Hintzen S, Heigel H, Franzke N, Schafer I,. Prevalence of skin lesions and need for treatment in a cohort of 90,880 workers. Br J Dermatol 2011; 165: 865-938.
4. Lebwohl M,. Psoriasis. Lancet. 2003; 361: 1197-1204. (Pubitemid 36398393)
5. Schmid-Ott G, Malewski P, Kreiselmaier I, Mrowietz U,. Psychosocial consequences of psoriasis-an empirical study of disease burden in 3753 affected people. Hautarzt 2005; 56: 466-472. (Pubitemid 40775566)
6. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM,. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-407. (Pubitemid 29418506)
7. Nast A, Kopp IB, Augustin M, et al. Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges 2007; 5 (Suppl 3): 1-119. (Pubitemid 47033875)
8. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
9. Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W,. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159: 513-526.
10. Spuls PI, Witkamp L, Bossuyt PM, Bos JD,. A systematic review of five systemic treatments for severe psoriasis. Br J Dermatol 1997; 137: 943-949. (Pubitemid 28011136)
11. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl 2): 1-70.
12. Spuls PI, Tuut MK, van Everdingen JJ, de Rie MA,. The practice guideline 'Photo(chemo)therapy and systemic therapy in severe chronic plaque-psoriasis'. Ned Tijdschr Geneeskd 2004; 148: 2121-2125. (Pubitemid 39433782)
13. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
14. Nast A, Boehncke WH, Mrowietz U, et al. S3-guidelines for the treatment of psoriasis vulgaris Update 2011. J Dtsch Dermatol Ges 2011; 9 (Suppl 2): S1-104.
15. Nijsten T, Looman CW, Stern RS,. Clinical severity of psoriasis in last 20 years of PUVA study. Arch Dermatol 2007; 143: 1113-1121. (Pubitemid 47443362)
16. Menter A, Griffiths CE,. Current and future management of psoriasis. Lancet 2007; 370: 272-284. (Pubitemid 47071926)
17. Chong BF, Wong HK,. Immunobiologics in the treatment of psoriasis. Clin Immunol 2007; 123: 129-138. (Pubitemid 46591957)
18. Gordon KB, Bonish BK, Patel T, Leonardi CL, Nickoloff BJ,. The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Brit J Dermatol 2005; 153: 945-953. (Pubitemid 41540759)
19. Clemmensen A, Spon M, Skov L, Zachariae C, Gniadecki R,. Responses to ustekinumab in the anti-TNF agent-naive vs. anti-TNF agent-exposed patients with psoriasis vulgaris. J Eur Acad Dermatol Venereol 2011; 25: 1037-1077.
20. Papoutsaki M, Talamonti M, Giunta A, et al. The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab. Dermatology 2010; 221 (Suppl 1): 43-47.
21. Nast A, Rosumeck S, Sammain A, Erdmann R, Sporbeck B, Rzany B,. S3-guidelines for the treatment of psoriasis vulgaris-methods report. J Dtsch Dermatol Ges 2011; 9 (Suppl 2): e64-84.
22. Augustin M, Kruger K, Radtke MA, Schwippl I, Reich K,. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008; 216: 366-372. (Pubitemid 351630108)
23. Higgins JPT, Green S,. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. The Cochrane Collaboration, 2011; http://www.cochrane-handbook.org, Chapter 9.6.4 Meta-regression.
24. Vena GA, Cassano N, Galluccio A, et al. Evaluation of the efficacy and tolerability of a new intermittent treatment regimen with cyclosporin A in severe psoriasis. Giornale Italiano di Dermatologia e Venereologia 2005; 140: 575-582. (Pubitemid 43942772)
25. Altmeyer P, Hartwig R, Matthes U,. Das Wirkungs- und Sicherheitsprofil von Fumarsäureestern in der oralen Langzeittherapie bei schwerer therapieresistenter Psoriasis vulgaris. Eine Untersuchung an 83 Patienten. Hautarzt 1996; 47: 190-196. (Pubitemid 26117567)
26. Carboni I, De Felice C, De Simoni I, Soda R, Chimenti S,. Fumaric acid esters in the treatment of psoriasis: an Italian experience. J Dermatolog Treat 2004; 15: 23-26. (Pubitemid 38252091)
27. Litjens NH, Nibbering PH, Barrois AJ, et al. Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines. Br J Dermatol 2003; 148: 444-451. (Pubitemid 36461322)
28. Ho SGY, Yeung CK, Chan HHL,. Methotrexate versus traditional Chinese medicine in psoriasis: A randomized, placebo-controlled trial to determine efficacy, safety and quality of life. Clini Exp Dermatol 2010; 35: 717-722.
29. Papoutsaki M, Chimenti MS, Costanzo A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 2007; 57: 269-275. (Pubitemid 47048857)
30. Mazzotta A, Esposito M, Costanzo A, Chimenti S,. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study. Am J Clin Dermatol 2009; 10: 319-324.
31. Berends MA, Driessen RJ, Langewouters AM, Boezeman JB, Van De Kerkhof PC, De Jong EM,. Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice. J Dermatolog Treat 2007; 18: 76-83. (Pubitemid 46801841)
32. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022. (Pubitemid 37448924)
33. Feldman SR, Kimball AB, Krueger GG, Woolley JM, Lalla D, Jahreis A,. Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol 2005; 53: 887-889. (Pubitemid 41501389)
34. Gisondi P, Del Giglio M, Cotena C, Girolomoni G,. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol 2008; 158: 1345-1349. (Pubitemid 351692891)
35. Vena GA, Galluccio A, De Simone C, et al. A multicenter open-label experience on the response of psoriasis to Adalimumab and effect of dose escalation in non-responders: the Aphrodite project. Int J Immunopathol Pharmacol 2009; 22: 227-233.
36. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606. (Pubitemid 44436647)
37. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304-1312. (Pubitemid 40933433)
38. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-1632. discussion 1632. (Pubitemid 37523083)
39. van de Kerkhof PC, Segaert S, Lahfa M, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 2008; 159: 1177-1185.
40. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719-726. (Pubitemid 46955730)
41. Krueger GG, Langley RG, Finlay AY, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 2005; 153: 1192-1199. (Pubitemid 41779576)
42. Koo J,. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. Br J Dermatol 1998; 139: 88-95. (Pubitemid 28338069)
43. Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G,. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr 2008; 88: 1242-1247.
44. Prinz JC, Fitzgerald O, Boggs RL, et al. Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial. J Eur Acad Dermatol Venereol 2011; 25: 559-564.
45. Ortonne J-P, Griffiths CEM, Dauden E, et al. Efficacy and safety of continuous versus paused etanercept teatment in patients with moderate-to-severe psoriasis over 54 weeks: The CRYSTEL study. Expert Rev Dermatol 2008; 3: 657-665.
46. Dauden E, Griffiths CE, Ortonne JP, et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol 2009; 23: 1374-1382.
47. Gelfand JM, Kimball AB, Mostow EN, et al. Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. Value Health 2008; 11: 400-407. (Pubitemid 351712967)
48. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374. (Pubitemid 41443403)
49. Reich K, Nestle FO, Papp K, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol 2006; 154: 1161-1168. (Pubitemid 43727400)
50. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674. (Pubitemid 351671883)
51. Lebwohl M, Papp K, Han C, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol 2010; 162: 137-146.
52. Torii H, Nakagawa H,. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci 2010; 59: 40-49.
53. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56: 31-e31.
54. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-1684. (Pubitemid 351671884)
55. Feldman SR, Gottlieb AB, Bala M, et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol 2008; 159: 704-710.
56. Bianchi L, Giunta A, Papoutsaki M, Costanzo A, Chimenti S,. Efficacy and safety of long-term infliximab therapy in moderate to severe psoriasis and psoriatic arthritis. Giornale Italiano di Dermatologia e Venereologia 2006; 141: 73-78.
57. Rustenbach SJ, Heyer K, Reppenhagen K, Augustin M,. Registerforschung in der Dermatologie. Hautarzt 2011; 62: 189-195.
58. van Lumig P, Driessen R, Berends M, Boezeman J, van de Kerkhof P, de Jong E,. Safety of treatment with biologics for psoriasis in daily practice: 5-year data. J Eur Acad Dermatol Venereol 2012; 26: 283-374.